Lixte Competitors
LIXT Stock | USD 3.28 0.06 1.86% |
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Lixte Biotechnology competition on your existing holdings.
Lixte |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Lixte Biotechnology's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Lixte Biotechnology Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Lixte Biotechnology and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Lixte and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Lixte Biotechnology does not affect the price movement of the other competitor.
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Lixte Stock performing well and Lixte Biotechnology Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Lixte Biotechnology's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
ALLR | 4.21 | (2.94) | 0.00 | (0.58) | 0.00 | 4.70 | 36.87 | |||
NRBO | 5.17 | (0.01) | 0.03 | 0.08 | 5.28 | 9.12 | 81.23 | |||
HILS | 3.73 | (0.62) | 0.00 | (41.10) | 0.00 | 7.89 | 24.20 | |||
VRAX | 3.28 | (0.59) | 0.00 | 6.64 | 0.00 | 6.15 | 27.96 | |||
QNRX | 3.99 | (2.17) | 0.00 | 1.08 | 0.00 | 4.69 | 53.64 | |||
INDP | 4.37 | 0.63 | 0.11 | 8.57 | 4.53 | 12.90 | 24.83 | |||
KTTA | 3.49 | 0.07 | 0.00 | 0.36 | 3.89 | 9.51 | 22.47 | |||
KRBP | 3.59 | (1.10) | 0.00 | (0.57) | 0.00 | 6.78 | 24.57 | |||
BDRX | 6.36 | (0.67) | 0.00 | (1.07) | 0.00 | 10.69 | 107.49 | |||
PMVP | 3.01 | 0.16 | 0.04 | 0.23 | 3.64 | 7.45 | 21.67 |
Cross Equities Net Income Analysis
Compare Lixte Biotechnology and related stocks such as Allarity Therapeutics, Neurobo Pharmaceuticals, and Hillstream Biopharma Net Income Over Time
Select Fundamental2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ALLR | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (5.1 M) | (26.6 M) | (16.1 M) | (11.9 M) | (12.5 M) |
NRBO | (320 K) | (320 K) | (320 K) | (320 K) | (320 K) | (9 M) | (14.6 M) | (33.4 M) | (23.6 M) | (22.4 M) | (29.6 M) | (15.2 M) | (6.1 M) | (12.5 M) | (13.1 M) |
VRAX | (801.1 K) | (801.1 K) | (801.1 K) | (801.1 K) | (801.1 K) | (801.1 K) | (801.1 K) | (801.1 K) | (801.1 K) | (801.1 K) | (651 K) | (1.7 M) | (5.5 M) | (4.9 M) | (4.7 M) |
QNRX | 15.3 M | 15.3 M | 15.3 M | 15.3 M | 15.3 M | 15.3 M | 15.3 M | 10.2 M | 15.3 M | (1.6 M) | (1.8 M) | (8.5 M) | (9.3 M) | (8.7 M) | (8.2 M) |
INDP | (47.6 M) | (47.6 M) | (47.6 M) | (47.6 M) | (47.6 M) | (47.6 M) | (47.6 M) | (47.6 M) | (47.6 M) | (47.6 M) | (3.6 M) | (7.7 M) | (13.7 M) | (15.4 M) | (16.2 M) |
KTTA | (41 K) | (41 K) | (41 K) | (41 K) | (41 K) | (41 K) | (41 K) | (41 K) | (41 K) | (41 K) | (41 K) | (2.2 M) | (13.1 M) | (16 M) | (15.2 M) |
BDRX | (4 M) | (4 M) | (4 M) | (4.1 M) | (8.8 M) | (10.1 M) | (6.2 M) | (11.7 M) | (10.4 M) | (9.1 M) | (22.2 M) | (5.5 M) | (7.7 M) | (7.1 M) | (7.4 M) |
PMVP | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (25.4 M) | (34.4 M) | (57.8 M) | (73.3 M) | (69 M) | (72.4 M) |
OLMA | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (4.3 M) | (22.8 M) | (70.9 M) | (102.6 M) | (96.7 M) | (91.8 M) |
SRRK | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (25 M) | (49.3 M) | (49.7 M) | (85 M) | (131.8 M) | (131.6 M) | (165.8 M) | (157.5 M) |
PASG | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (54.6 M) | (111.8 M) | (191.5 M) | (136.9 M) | (102.1 M) | (107.2 M) |
Lixte Biotechnology and related stocks such as Allarity Therapeutics, Neurobo Pharmaceuticals, and Hillstream Biopharma Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Lixte Biotechnology financial statement analysis. It represents the amount of money remaining after all of Lixte Biotechnology Holdings operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Lixte Biotechnology Competitive Analysis
The better you understand Lixte Biotechnology competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Lixte Biotechnology's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Lixte Biotechnology's competition over several years is one of the best ways to analyze its investment potential.Better Than Average | Worse Than Peers | View Performance Chart |
Lixte Biotechnology Competition Performance Charts
Five steps to successful analysis of Lixte Biotechnology Competition
Lixte Biotechnology's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Lixte Biotechnology in relation to its competition. Lixte Biotechnology's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Lixte Biotechnology in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Lixte Biotechnology's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Lixte Biotechnology, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Lixte Biotechnology position
In addition to having Lixte Biotechnology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Investor Favorites Thematic Idea Now
Investor Favorites
Macroaxis most traded equities with largest long positions over the last 2 years. The Investor Favorites theme has 21 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Investor Favorites Theme or any other thematic opportunities.
View All Next | Launch |
Check out Lixte Biotechnology Correlation with its peers. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Complementary Tools for Lixte Stock analysis
When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.
Transaction History View history of all your transactions and understand their impact on performance | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |
Is Lixte Biotechnology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lixte Biotechnology. If investors know Lixte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lixte Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.66) | Return On Assets (0.64) | Return On Equity (1.11) |
The market value of Lixte Biotechnology is measured differently than its book value, which is the value of Lixte that is recorded on the company's balance sheet. Investors also form their own opinion of Lixte Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Lixte Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lixte Biotechnology's market value can be influenced by many factors that don't directly affect Lixte Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lixte Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lixte Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lixte Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.